ArticleDiabetologia2026
Interpericyte tunnelling nanotube loss in very early diabetic retinal disease.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisInterpericyte tunnelling nanotubes (IP-TNTs) regulate microvascular blood flow by coordinating pericyte-pericyte communication across distant capillaries in the retina. Perfusion abnormalities are observed in preclinical diabetic retinopathy, and the state of IP-TNTs in this condition is unknown.
methodsUsing high-resolution confocal microscopy with isolated perfusion labelling of human donor retina, we investigated changes to IP-TNTs, pericytes and capillaries in the macular vasculature of individuals with preclinical diabetic retinopathy (n=7) and control individuals (n=12).
resultsWe observed diffuse loss of IP-TNTs in the superficial vascular plexus (SVP), the intermediate capillary plexus (ICP) and the deep capillary plexus (DCP) as well as in the four quadrants of the macula in preclinical diabetic retinopathy. The mean ± SD numbers of IP-TNTs per 500 × 500 µm area were 2.5 ± 0.79 (diabetic) and 3.93 ± 0.82 (control) (p<0.0001) in the SVP; 1.40 ± 0.83 (diabetic) and 1.98 ± 0.88 (control) (p=0.012) in the ICP; and 1.11 ± 0.87 (diabetic) and 1.75 ± 0.99 (control) (p=0.011) in the DCP. Within the ICP and DCP, IP-TNT losses were identified despite an absence of pericyte density changes. In the SVP, IP-TNT losses were present despite an absence of capillary density change. CONCLUSIONS/
interpretationThese observations suggest that IP-TNT loss is a very early feature of diabetic retinopathy that can selectively precede alterations to pericytes and retinal capillaries. Given that IP-TNTs are intimately associated with pericytes, there is the potential that IP-TNT loss contributes to perfusion abnormalities and may be one of the major pathogenic factors in diabetic retinopathy. Future studies should confirm this exploratory work; the development of therapeutic agents designed to maintain IP-TNT structure and function may be an important factor for the preservation of retinal health.
Indexed as
Identifiers
41266664What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.